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 INTRODUCTION 
 
 Laryngeal mask airway, a new supraglottic airway device that has 
been added to the anaesthesiologists armamentarium, was invented by 
Dr. Archie Brain in 1983. Initially laryngeal mask airway was 
recommended as a better alternative to face mask for airway management 
in anaesthetized patients.  Soon after its introduction into the clinical 
practice in 1988, the laryngeal mask airway has been found to be a more 
effective ventilating device than the face mask. LMA causes less 
stimulation of protective airway reflexes and the cardiovascular system 
than the endotracheal tube. 
 
 The insertion of laryngeal mask airway stimulates the hard and soft 
palate, posterior pharyngeal wall and hypopharynx and the depth of 
anaesthesia required is less compared to endotracheal intubation.  The 
another advantage of laryngeal mask airway insertion over endotracheal 
intubation is muscle relaxant may be optional. 
 
 
 
  For successful laryngeal mask airway insertion and placement, 
intravenous induction agents like propofol and thiopentone along with 
opioids, midazolam  and  lignocaine are used. 
  
The purpose of this prospective study is to compare LMA inserting 
conditions and haemodynamic changes with sevoflurane(8%) and  
propofol.  This study is undertaken with utmost care and the results are 
discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
AIM OF THE STUDY 
 
 To compare sevoflurane (8%) and propofol (2 mg/kg) as an 
induction agent for the laryngeal mask airway insertion. The induction 
time, overall ease of LMA insertion, placement  and  haemodynamic 
changes are taken as parameters and compared. 
 Fentanyl and Midazolam are used as common adjuvants in both the 
groups in the same doses. 
 
 
 
 
          
 
 
 ANATOMY 
ORAL CAVITY 
 The oral cavity or buccal cavity, consists of a narrow vestibule 
outside the teeth and an inner large oral cavity proper.  The oral cavity 
proper is bounded in front and laterally by the alveolar arches, teeth and 
gums; behind it communicates with the pharynx at the oropharyngeal 
isthumus.  It’s roof is formed by the hard and soft palates.  Its floor is 
mainly formed by the anterior region of the tongue and the remainder by 
the mucosa lying on the mylohyoid anteriorly and laterally between the 
base of the tongue and the internal surface of the mandible on to which it 
is reflected. 
PALATE 
 The palate or the oral roof is divisible into two regions, the hard 
palate and soft palate. 
Hard Palate  
 It is formed by the palatine process of the maxillae and the 
horizontal plates of the palatine bones.  It is bounded in front and at the 
sides by the superior and inferior arches of the alveolar processes and 
gums and is continues posteriorly with the soft palate.  It is covered with 
stratified squamous epithelium. 
 Soft Palate : 
 It is a mobile flap suspended from the posterior borders of the hard 
palate, sloping down and backwards between the oral and nasal parts of 
the pharynx. It is a thick fold of mucosa enclosing an aponeurosis, 
muscular tissue vessels, nerves, lymphoid tissue and mucous glands. In 
its usual position, released and pendant, its anterior surface is concave 
with a median raphe, its posterior surface is convex and continues with 
the nasal floor. Its anterosuperior border is attached to the hard palate’s 
posterior margin, its sides blend with the pharyngeal wall and its inferior 
border is free hanging between the mouth and pharynx.  A median 
conical process, the uvula projects downwards from its posterior border. 
 
 The arch of the palate curves as two folds of mucosa containing 
muscle, which descends laterally from each side of the soft palate.  The 
anterior palatal arch, contains palatoglossus muscle which descends to the 
side of the tongue at the junction of its oral and pharyngeal parts forming 
lateral limits of the oropharyngeal isthumus.  The posterior 
palatopharygeal arch contains the palatopharyngeus muscle and descends 
on the lateral wall of oropharynx. 
 
 Nerve Supply : 
 The sensory nerve issue from the greater, lesser palatine and 
nasopalatine branches of the maxillary nerve and also the 
glossopharyngeal nerve posteriorly.  Parasympathetic post ganglionic 
secretomotor fibres arising from the fascial nerve supply the palatine 
mucus glands via the pterygopalatine ganglion. It is also possible that 
some parasympathetic fibres pass to the posterior parts of the soft palate 
from the glossopharyngeal nerve perhaps synapsing in the otic ganglion. 
Sympathetic fibres run from the carotid plexus along the arterial branches 
supplying this region. 
 All the palatine muscles are supplied by nerve fibres which leave 
the medulla in the cranial part of accessory nerve and reach the 
pharyngeal plexus via the vagus and possibly glossopharyngeal nerve 
except for the tensor vali palati which is innervated by the mandibular 
nerve. 
PHARYNX : 
 It is situated behind the nasal cavities, mouth and larynx, a 
musculomembranous tube 12-14 cm long, extending from the cranial 
base to the level of the sixth cervical vertebra and the lower border of 
cricoid cartilage where it continuous with the oesophagus. 
 Oropharynx : 
 Oropharynx extends from the soft palate to the upper border of the 
epiglottis.  It opens into the mouth through the oropharyngeal isthumus.  
It’s lateral wall consists of the palatopharyngeal arch and palatine tonsils.  
Posteriorly it is in level with the body of second and upper part of the 
third cervical vertebrae. 
 
Laryngopharynx : 
 Laryngeal part of the pharynx extends from the superior border of 
epiglottis to the inferior border of cricoid cartilage where it becomes 
continuous with the esophagus.  In its incomplete anterior wall is the 
laryngeal inlet and below this is the posterior surface of the arytenoids 
and cricoid cartilage. A small pyriform fossa on each side of the inlet is 
bounded medially by the aryepiglottic fold and laterally by the thyroid 
cartilage and thyrohyoid membrane. 
Muscles : 
 Pharynx consists of three constrictor muscles superior, middle and 
inferior and a trio of muscles descending from styloid processes.  It also 
contains cartilaginous tissue of pharyngotympanic tube and muscles or 
soft palate like stylopharyngeus, salpingopharyngeus, and 
 palatopharyngeus. All the above mentioned muscles pass obliquely into 
the muscular wall. 
 
Nerve supply of the pharynx : 
 Innervation is mainly from the pharyngeal plexus.  The principal 
motor element is the cranial part of the accessory nerve, which through 
vagal branches supplies all pharyngeal and palatine muscles except the 
stylopharyngeus (glossopharyngeal nerve) and the tensor valitympani 
(mandibular nerve).  The main sensory nerves are the glossopharyngeal 
nerve and vagus.  The mucosa of nasopharynx is supplied by maxillary 
nerve via the pterygopalatine ganglion.  The mucosa of the soft palate 
and the tonsil is supplied by the lesser palatine and glossopharyngeal 
nerve. 
Nerve supply of Larynx : 
Nerve Sensory Motor 
Superior laryngeal 
(internal division) 
Epiglottis, base of tongue, 
supraglottic mucosa, 
thyroepiglottic joint, 
cricothyroid joint 
None 
Superior laryngeal 
(External division) 
Anterior subglottic mucosa Cricothyroid (Adductor, 
Tensor) 
 Recurrent laryngeal Subglottic mucosa,  muscle 
spindles 
Thyro arytenoid, lateral 
crico arytenoid, inter 
arytenoid (adductor), 
 Posterior cricoarytenoid 
(abductor) 
 
TRACHEA : 
 It is a tubular structure that begins opposite the sixth cervical 
vertebra at the level of the thyroid cartilage.  It is flattened posteriorly and 
supported along its 10-15 cm length by 16-20 horseshoe-shaped 
cartilaginous rings until its bifurcation into right and left main bronchi. 
Receptors in the trachea are sensitive to mechanical and chemical stimuli.  
Slowly adapting stretch receptors are located in the trachealis muscle of 
the posterior tracheal wall.  These are involved in regulating the rate and 
depth of breathing, but they also produce dilatation of upper airways and 
bronchi by decreasing vagal efferent activity.  Other rapidly adapting 
irritant receptors lie all around the tracheal circumferences.  They are 
usually considered to be cough receptors, although their other reflex 
actions consist of bronchoconstriction. 
 
 
 LARYNGEAL MASK AIRWAY 
History and Concepts : 
 Endotracheal intubation has a long history as one of the most wide 
accepted techniques in anaesthesia.  But after the invention of LMA, 
routine use of endotracheal intubation has been replaced by insertion of 
LMA. 
 Dr. A.I.J. BRAIN viewed the mechanical aspects of endotracheal 
intubation in which an artificial tube is inserted into the trachea, the 
natural tube, and a cuff being inflated to form a gas tight seal.  He found 
that in engineering terms, this solution to the problem of forming a gas 
tight junction between two tubes is rather unsatisfactory, since it 
necessarily involves a degree of constriction at the point of junction 
unless the outer tube (trachea) itself is expanded to compensate.  He felt, 
ideally, it is desirable that both tubes are of the same internal diameter at 
the point of their junction, since this has clear advantages in terms of gas 
flow without constriction in the tubes.  This involves connecting them 
end to end since the option of expanding the anatomical tube (trachea) is 
not possible. 
 Based on the above concepts of the airway, Dr. BRAIN tried to 
produce an airway, which directly faced the larynx yet it should provide a 
 gas-tight seal.  He examined the postmortem specimens of adult male and 
female larynx to assess how such a joint might be achieved. He examined 
the shape of the pharynx by making plaster of paris casts from these 
specimens (cadavers).  He noted that an airtight seal could be effected 
against the perimeter of the larynx posteriorly by an elliptical cuff 
inflated in the hypopharynx. This observation led to the concept of 
laryngeal mask airway. 
The Prototype of the Laryngeal Mask : 
 A prototype of the laryngeal mask was constructed by Dr. BRAIN, 
by forming a shallow mask with an inflatable rubber cuff joined to a tube 
communicating with the lumen of the mask at right angles.  The rubber 
cuff of a Goldman paediatric dental mask was stretched onto the 
diagonally cut endotracheal end of portex 10 mm clear plastic tube and 
fixed in position using acrylic glue.  The resulting apparatus resembles a 
spoon.   
 Dr.BRAIN invented this prototype of laryngeal mask in the year 
1981 based on the cast model of the hypopharynx and in the same year he 
used this prototype in a patient for the first time.  Brain confirmed in 
cadavers that the mask of prototype was long enough to encircle the 
larynx, because the length between the tip of the masks and the upper 
 border of the mask aperture was always longer than that of between the 
upper border of thyroid cartilage and lower border of cricoid cartilage. 
DESIGN AND DESCRIPTION : 
 The laryngeal mask airway is designed to secure the airway by 
establishing end to end circumferential seal around the laryngeal inlet 
with an inflatable cuff.  It is an useful advance in airway management 
filling a niche between the face mask and tracheal tube in terms of both 
anatomical position and the degree of invasiveness. 
Description : 
Standard Laryngeal Mask Airway : 
 The laryngeal mask airway (LMA) consists of a curved tube 
connected to an elliptical spoon shaped mask at a 30o angle. This angle 
was chosen because it was found to be an optimal angle for tracheal 
intubation through LMA. There are two flexible vertical bars at the entry 
of the tube into the mask to prevent obstruction of the tube by the 
epiglottis.  The mask is surrounded by an inflatable cuff.  When the cuff 
is correctly deflated, it should form a “water thin leading edge” falling 
away from the mask aperture.  An inflation tube and self sealing pilot 
balloon are attached to the proximal wider end of the mask.  A black line 
running longitudinally along the posterior aspect of the tube helps to  
 orient it after placement.  At the machine end of the tube is a standard 15 
mm connector. 
 The LMA is made from the medical-grade silicone to with stand 
repeated steam autoclaving and contains no latex.  The LMA incorporates 
polysulfone connector and propylene valve.  The LMA is available in 8 
sizes.  More than one size should always be available because the correct 
size cannot always be predicted accurately.  When there is a doubt, a 
larger rather than a smaller size should be chosen for the first attempt. 
Size ID 
(mm) 
OD 
(mm) 
Length 
(cm) 
Cuff 
volume 
Patient size 
1 5.25 8.2 8.8 Upto 4 ml Neonates / infants upto 5 kg 
1.5 6.1 9.6 10 Upto 7 ml Infants  between 5-10 kg 
2 7 11 11 Upto 10ml Infants and children between 
10-20 kg 
2.5 8.4 13 12.5 Upto 14 ml Children between 20-30 kg 
3 10 15 16 Upto 20 ml Children, small adults over 30 
kg 
4 10 15 16 Upto 30 ml Normal adults weighing 50-70 
kg 
5 11.5 16.5 18 Upto 40 ml Adults weighing 50-70 kg 
6 11.5 16.5 18 Upto 50 ml Large adults over 100 kg 
 
Modified Versions : 
 There are several variants of LMA. These includes 
 LMA Unique : 
 This is a disposable LMA for single use, available as a presterilized 
pack in sizes 3, 4 and 5. The cuff of this LMA is made from PVC.  It has 
been designed for use in emergency airway management inside and 
outside the operating room. 
LMA safe guard  
 It is a new variant of LMA unique recently introduced by Intavent 
company for the purpose of easy department recognition. Different colour 
coding of pilot balloon indicates various departments in the hospital. 
 Dark blue  - Theatres 
 Pale Blue  - Day case surgery 
 Yellow non metallic- MRI Room 
 Green  - Cardiopulmonary resuscitation 
Flexible LMA : 
 The flexible (Wire-reinforced) LMA differs from the standard 
version that it has a flexible, wire reinforced tube.  In each size the tube is 
longer and has a smaller diameter than the standard LMA.  The flexible 
LMA can be bent to any angle allowing it to be positioned away from the 
surgical field without occluding the lumen or losing the seal against the 
larynx. 
 It is likely to be displaced during rotation of the head or 
repositioning of the tube than standard LMA.  The wire reinforcement 
makes the tube more resistant to kinking and compression than standard 
LMA. 
 
Short Tube LMA : 
 It has a tube that is 2 cm shorter than the standard LMA.  It is 
designed to allow proper positioning of tracheal tube passed through it.  
An endotracheal tube passed into the standard LMA may not reach the 
level of the mid trachea because of the length of LMA tube.  The short 
tube LMA has been designed to circumvent this problem.  It is available 
in size 3. 
 
Intubating LMA: 
 This has been specially designed to aid endotraheal intubation with 
an appropriate size tube without any manipulation of the head and neck 
during placements.  It consists of a rigid stainless steel airway tube and a 
metallic handle specially designed for intubation. The convex radius of 
the curve of the metal tube is 41.5 mm.  The tube is curved around a 
minimum arc of 128o corresponding to the approximate alignment axis.  
 This curve avoids the need for head and neck manipulation and permits 
the intubating LMA to be placed with the head in neutral position.  The 
minimum internal diameter of the tube is 13 mm with a wall thickness of 
< 1 mm.  This accepts upto    8 mm internal diameter cuffed tracheal 
tube. Stainless steel was chosen because of its compatibility with silicon, 
high strength, malleability, ease of sterilization and cleaning and absence 
of toxicity. The tube is covered with a silicone sheeth to minimize trauma 
and facilitate secure bonding with the mask portion, giving an outer 
diameter of 17.6mm.  There is an integral stainless steel 15 mm connector 
which corresponds to the proximal end of the tube.  This permits its use 
as a standard LMA and avoids risk of accidental disconnection.  
 In the place of the aperture bars of the standard LMA the intubating 
LMA consist of a single epiglottis elevating bar (EEB) attached only at 
the upper rim of the mask, so that its free end can be swung out by the 
advancing tracheal tube, pushing the epiglottis out of the way as it does 
so. The passage immediately behind the EEB is provided with a ‘V’ 
shaped 20o guiding ramp in its floor, which centres the tracheal tube and 
guides the tube anteriorly to reduce risk of arytenoids trauma and 
oesophageal placement. 
  Specially manufactured straight, soft, wire reinforced cuffed 
silicone tracheal tubes are used when intubating through the intubating 
LMA.  Silicone significantly retains the curvature imposed by passage 
through the metal airway tube, even when the tubes are warmed to 37oC. 
 The tracheal tube is marked transversely with a depth marker to 
show the user, the point at which the tip of tracheal tube is about to lift 
away the EEB.  In addition, a longitudinal line similar to the black line on 
an LMA tube is provided to serve as a guide to the orientation of the 
tracheal tube level.  The pilot balloon and valve are small enough to pass 
easily through the metal tube of the intubating LMA, and the tracheal 
tube connector is removable in order that the intubating LMA could be 
removed from the patient when intubation has been achieved. 
 
 
LMA PRO – SEAL 
 It is an advanced form of LMA that may be used for the same 
indications as the original LMA.  It has been specifically designed for use 
with positive pressure ventilation with and without muscle relaxant at 
higher airway pressures.  It does not however protect the airway from the 
effect of regurgitation and aspiration. 
  The LMA proseal has four main components, cuff, inflation line 
with pilot balloon, airway tube and drain tube. The cuff is made of a 
softer material than the standard LMA.  The mask has a main cuff that 
seals around the laryngeal opening and a rear cuff that acts to increase the 
seal. Attached to the mask is an inflation line terminating in a pilot 
balloon which inflates and deflates the mask via a valve.  Within the 
mask, a drain tube provides a conduit that communicates with the upper 
oesophageal sphincter. The airway tube is wire reinforced which resists 
kinking and terminates with a standard 15 mm airway connector.  The 
position of the drain tube inside the cuff is designed to prevent the 
epiglottis from occluding the airway tube. This eliminates the need for 
aperture bars. 
 Accessories to the LMA proseal include a removable introducer to 
aid insertion of the LMA proseal without the need to place fingers in the 
mouth and a deflation device to obtain complete deflation of the LMA-
proseal for successful sterilization, optimum insertion and positioning 
within the patient.  The revised cuff arrangement allows a higher seal 
than the standard LMA for a given intra cuff pressure.  The drain tube 
communicates with the upper oesophageal sphincter and permits venting 
of the stomach and blind insertion of standard gastric tubes in any patient 
 position without the need to use Magill’s forceps.  The double tube 
arrangement reduces the likelihood of device rotation; the revised cuff 
profile, together with the two tubes, results in the device being more 
securely anchored in place. 
 The LMA pro-seal can be introduced with the help of the 
introducer or using the thumb and forefinger in the same manner as that 
used for standard LMA. 
ANATOMY 
 When LMA is correctly positioned, the upper part of the mask lies 
under the base of the tongue, allowing the epiglottis to rest within the 
bowl of the mask.  The LMA sits in the hypopharynx at the junction of 
the gastrointestinal and respiratory tracts, where it forms a 
circumferential low pressure seal around the glottis when inflated it lies 
with the tip resting against the upper esophageal sphincter, the sides 
facing the pyriform fossa. Epiglottic down folding occurs in 12% to 60% 
of cases but is rarely associated with clinical airway obstruction.  Over 
pressure (>25 cm H2O) applied by ventilation may displace the LMA and 
expose the oesophagus. 
 Dye studies have demonstrated that LMA cuff acts as an airtight 
throat pack and forms an effective seal across the pharynx. 
  When positioned correctly, the tip of the LMA cuff lies at a 
variable depth behind the cricoid cartilage, the application of cricoid 
pressure may therefore potentially reduce the ease of insertion of the 
LMA. 
 
Inspection Before Use : 
Before it is used, the LMA should be inspected carefully.  The first 
step is to examine the tube.  It should be transparent so that particles or 
fluids within it can be seen. The interior of the tube should be free from 
obstruction or foreign particles and the exterior should be free from 
cracks, abrasions or foreign material. When the tube is flexed at 180o, 
kinking should not occur.  
The next test is to examine the aperture. The epiglottic bars should 
be probed gently to make certain that they are not damaged and the space 
between them is free from particulate matter.  In the next step the valve 
should be tested and replaced if the cuff reinflates spontaneously after 
being completely deflated. 
The next step is to inflate the cuff with the maximum amount of air 
the cuff should contain. After the cuff is filled, it should hold pressure for 
at least 2 minutes. If not, the LMA should not be used. 
 The integrity of the cuff should be verified by inflating with a 
volume of air 50% greater than the recommended maximum volume.  
Any herniation, thinning of the wall or asymmetry in an indication to 
discard the LMA. 
The next step is to check the pilot balloon diameter with the cuff 
50% over inflated, the balloon should be elliptical, not spherical. The 
transverse diameter should not exceed 14.5 mm at its widest point.  
Excessive width of pilot balloon indicates weakness and imminent 
rupture. 
Preparation of Mask : 
The cuff should be fully deflated with a dry syringe to form a flat 
oval disc by pressing the hollow side down firmly against a clean, hard 
flat surface with a finger pressing the tip flat.  The deflated cuff should be 
wrinkle free to facilitate its passage and avoid bruising tissues. 
Lubrication should be applied to the posterior surface of the cuff just 
before insertion, taking care to avoid getting lubricant on the anterior 
surface. Lubrication with lidocaine gel will result in lower incidence of 
retaining coughing on emergence. 
 
 
 Laryngeal Mask Airway Insertion : 
Principle  
 LMA insertion can be considered in the context of swallowing.  In 
swallowing, the tongue acts as a semicircular ram sweeping and 
flattening the food bolus around the curved wall formed by the palate and 
posterior aspect of the pharynx.  Mask insertion is achieved by a similar 
action with the index finger substituting the action of the tongue.  
Insertion is relatively unstimulating because of avoidance of 
instrumentation and manipulation of structures associated with noxious 
reflex responses. The insertion of LMA does not require the use of a 
laryngoscope or a muscle relaxant. 
 
Standard Technique of Insertion : 
 It appears to offer superior results in terms of functional and final 
anatomical position in adults, an important consideration when using 
LMA as an aid to intubation. 
 The cuff should be fully deflated to form a flat oval disc by 
pressing the hollow side, down firmly against  a clean, hard, flat surface 
with a finger pressing the tip flat.  The deflated cuff tip should form a 
relatively stiff wedge so that it is capable of passing behind the epiglottis 
 even when it is lying against the posterior pharyngeal wall. The deflated 
cuff should also be wrinkle free to facilitate its passage and avoid 
bruising tissues. 
 Lubrication should be applied to the posterior surface of the cuff 
just before insertion, taking care to avoid getting lubricant on the anterior 
surface. This prevents the cuff tip from folding on to itself on-contact 
with palate and also results in a lower incidence of retching and coughing 
on emergence. After adequate general or topical anaesthesia and or 
complete muscle relaxation the patient’s neck is flexed and the head 
extended (sniffing position) by pushing the head from behind with the 
non-dominant hand.  An assistant should open the mouth by pulling the 
lower jaw downwards. With experience, the operator can open the mouth 
with the third finger of the dominant hand. 
 The tube portion is grasped as if it were a pen with the index finger 
pressing on the point where the tube join the mask.  With the aperture 
facing anteriorly and the black line facing the patients upper lip, the tip of 
the cuff is placed against the inner surface of the upper incisors or gums. 
At this point the tube should be parallel to floor rather than vertical. 
  The device is advanced using the index finger at the junction of the 
mask and the tube.  It is essential that the tip of the cuff does not roll over 
while advancing the LMA. 
 A change in direction will be felt as the cuff tip follow the posterior 
pharyngeal wall downwards. The LMA is pushed as far as possible into 
the hypopharynx by the index finger. When the mask is fairly advanced 
resistance will be felt. 
 The tube is then held by the non dominant hand to prevent the mask 
from moving out of position as the index finger is withdrawn. 
 The cuff is then inflated with an appropriate volume of air.  The 
tube usually moves out of the mouth slightly and the tissues overlying the 
thyroid and cricoid cartilage bulge slightly when the cuff is inflated. This 
confirms the mask position.  The tube should not be held or connected to 
the breathing system during inflation. 
 After inflating the cuff, the LMA is connected to the breathing 
system and adequacy of ventilation is assessed. 
 
 
 
 
 OTHER TECHNIQUES  
180 degree technique : 
 The LMA is inserted with the laryngeal aperture pointing cephalad 
and rotating it to 180o as it enters the pharynx. 
Partial inflation technique : 
 This has increased the success rate in some studies.  It may result in  
less sore throat but the incidence of down folding and trapping of 
epiglottis is increased. 
Maintenance of Anaesthesia with LMA  
 Both spontaneous breathing and intermittent positive pressure 
ventilation can be achieved through the LMA. If laryngospasm, 
wheezing, swallowing, coughing, straining or breath-holding occurs, 
anaesthesia should be deepened or muscle relaxant administered.  The 
patients upper abdomen should be periodically observed for signs of 
distension. 
Removal of LMA : 
 A bite block must be kept in place, until the LMA is removed. 
LMA is tolerated even in lighter planes of anaesthesia and can be left in 
place during emergence.  Some recommend that the LMA can be left in 
position until full recovery of airway reflexes has occurred and the 
 patient can phonate or open his mouth on command. The onset of 
swallowing is a useful predictor that such a level of wakefulness is 
imminent. 
Advantages of LMA over Endotracheal Tube : 
1. Placement of LMA is easier when compared to intubation 
2. LMA is a relatively non-invasive airway when compared to 
tracheal tube 
3. The respiratory system is less disturbed because the cords are 
not penetrated 
4. The haemodynamic changes, intracranial and intraocular 
pressure changes are less during LMA insertion than during 
intubation. 
5. The resistance to airflow is less in the standard LMA than that of 
corresponding tracheal tube. 
6. Less anaesthetic depth is required. 
7. Less anaesthesia is requires to tolerate LMA than tracheal tube 
8. Insertion of LMA does not cause significant bacteremia when 
compared to nasal intubation. 
9. Incidence  of sore throat and subsequent respiratory tract 
infection is less when compared to tracheal tube. 
 Disadvantages of LMA : 
2. Increased risk of gastrointestinal  aspiration 
3. LMA is unsafe in  prone or jack knife position 
4. Use of LMA in morbidly obese patients is unsafe 
5. Limits maximum positive pressure ventilation that can be 
applied during ventilation. 
 
Complications : 
1. Accidental  dislodgement can occur 
2. Airway obstruction and airway injury 
3. Nerve Injury - Palsies of hypoglossal, recurrent laryngeal 
and lingual nerves have been reported after the use of LMA. 
 
Indications : 
1. It includes routine, elective cases were tracheal intubation is not 
required or is required only because the surgery interferes with 
maintenance of the airway with a face mask. 
2. It is useful in cases where maintenance of airway with a face 
mask is difficult such as edentulous patients, facial injuries or 
burn. 
 3. Useful in elective eye surgeries since changes in intraocular 
pressure are smaller when compared to intubation. 
4. In patients having daily radiotherapy under general anaesthesia, 
the use of LMA can avoid repeated tracheal intubation. 
5. The LMA is now being advocated in anaesthesia for MRI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SEVOFLURANE 
[1,1,1,3,3,3, hexafluoro -2- (fluoromethoxy) propane] 
Sevoflurane was first synthesized in the late 1960s by R.F. Wallin and 
coworkers.  It was first used in humans in 1981.  It became the most 
popular inhalational agent in 1990. 
Physical Properties : 
 Sevoflurane is colorless, nonflammable and liquid at room 
temperature.  It is pleasant to inhale.  Its boiling point is 58.5o C and 
saturated vapour pressure is 21.3 kpa (160 mm Hg) at 20oC.  It has a 
blood gas solubility coefficient of 0.69 and hence induction and recovery 
will be very rapid.  It is less soluble in rubber and plastic anaesthetic 
circuits.  MAC of sevoflurane in adults varies between 1.7–2.1 which 
may be reduced by N2O, opioid drugs and hypnotics. 
Pharmacokinetics : 
 The anaesthetic concentrations are rapidly achieved since the blood 
gas partition coefficient is low.  At 30 min after the start of the 
anaesthesia, FA/FI for sevoflurane was 0.85 compared to that of 0.73 for 
isoflurane.  Hence set concentrations are achieved more quickly and 
elimination is also quicker. Sevoflurane is primarily excreted through the 
lung although a small amount is metabolized (1.6-4.9%) in liver to 
 inorganic fluoride ions and organic fluoride metabolite hexa 
fluroisopropanol (HFIP) which is excreted by the kidneys. 
Pharmacodynamics : 
Central Nervous system effects : 
 Sevoflurane significantly reduces cerebral metabolic rate for 
oxygen.  MAP and CPP are better maintained with sevoflurane than with 
isoflurane.  At minimal MAC, it does not increase the cerebral blood 
flow.  The cerebrovascular response to carbondioxide and cerebral 
autoregulation are both preserved under sevoflurane anaesthesia. 
Respiratory system : 
 Sevoflurane is suitable for inhalational induction since it has no 
irritant effects on the airway and blood gas solubility coefficient also low.  
It is a respiratory depressant, causes reduction in tidal volume and minute 
ventilation.  Sevoflurane abolishes the hypoxic pulmonary 
vasoconstriction in a dose dependent manner.  Though it is a 
bronchodilator it is not effective as halothane in attenuating changes in 
airway resistance. 
Cardiovascular system : 
 Sevoflurane has minimal effect on heart rate. It produces dose 
dependent myocardial depression through an effect on calcium channels, 
 thereby reducing the cardiac output and systemic vascular resistance.  It 
also causes reduction in pulmonary arterial pressure which is not dose 
dependent.  Hepatic and renal blood flows are well preserved upto 1 
MAC.  It doesn’t sensitise the myocardium to epinephrine.  It is also a 
coronary vasodilator. 
Neuromuscular effects : 
 Sevoflurane produces dose dependent muscle relaxation and also 
potentiates the action of neuromuscular blocking agents.  It prolongs the 
train of four recovery.  But it has no effect on recovery of post tetanic 
twitch which suggests its action is mainly on the post junctional region of 
the neuromuscular junction. 
 
Advantages : 
 It has low blood gas solubility coefficient hence induction and 
recovery are quicker. 
 It offers good haemodynamic stability 
 It contains no chloride ions and hence no effect on the ozone layer 
ie. environmental friendly. 
It is pleasant to inhale.  Therefore suitable for inhalational 
induction.  
 Of the halogenated anaesthetic agents currently in widespread use, 
sevoflurane is the only agent which is not metabolished to trifluroacetic 
acid which has been implicated in hepatotoxicity. 
 
Disadvantages : 
 When sevoflurane is exposed to sodalime or Baralyme, it is 
absorbed and degraded into fluoromethyl 2-2- difluoro-1-Vinyl ether 
(compound A) and fluromethyl-2-Methoxy 2-2 difluero-1-ethyl ether 
(compound B) which causes renal and lung damage. 
 Exposure to 1.25 MAC at a flow rate of 2 litre per minute for 4-8 
hours may produce renal injury. 
 Sevoflurane should be avoided in patients susceptible to malignant 
hyperthermia. 
 
 
 
 
 
 
 
 PROPOFOL 
 Propofol is 2, 6, di-isopropylphenol which was introduced into 
clinical practice in 1977 as 1% solution solubilized in cremophor EL.  
Due to anaphylactoid reactions associated with cremophor EL the drug 
was reformulated in an emulsion. 
Physiochemical Properties : 
 Propofol is an alkylphenol oil at room temperature, insoluble in 
aqueous solution but highly lipid soluble.  The present formulation 
consists of 1% propofol, 10% soyabean oil, 2.25% glycerol and 1.2% egg 
phosphatide.  It has pH of 7.0 and appears viscous, milky white 
substance. Its  pKa is 11. 
Pharmacokinetics : 
 The intravenous administration of single bolus induction dose of 
propofol is followed by rapid decrease in the blood level as a result of 
both redistribution and elimination. Propofol is 98% protein bound.  The 
alpha half time is 2.5 min and beta phase half time is 1-3 hrs.  The 
volume of distribution for propofol at steady state is 3.5 – 4.5 lit/kg. 
Propofol has very high clearance 30-60 ml/kg/min.  Propofol is rapidly 
metabolized in liver by conjugation to glucuronide and sulfate to produce 
water–soluble compounds which are excreted by kidneys. 
 Pharmacodynamics : 
 CNS :  Propofol in adequate dosage causes rapid onset of 
unconsciousness in 11-15 secs by enhancing the GABA activated 
chloride channel.  Propofol is not antianalgesic.  The excitatory 
phenomenon such as involuntary movements may be seen with induction. 
It produces dose related  depression in EEG.  The effect of propofol on 
epileptogenic EEG activity is controversial.  Propofol reduces the 
cerebral blood flow and CMRO2.  Propofol decreases ICP in patients with 
either normal or elevated ICP.  Intraocular pressure is also reduced with 
propofol.  Patients on awakening from anaesthesia appear to have less 
post operative sedation, are alert and show no hang over. Psychomotor 
function following propofol anaesthesia is good and recovery is rapid.  
Propofol produces low incidence of nausea, vomiting and headache. 
Respiratory System : 
 Propofol produces dose dependent respiratory depression.  There is 
marked initial reduction in tidal volume following a normal induction 
dose of propofol often amounting to a period of apnoea varying from 30-
60 sec.  The onset of apnoea is preceded by marked tidal volume 
reduction and tachypnoea.  Propofol depresses the ventilatory responses 
to hypoxia.  Respiratory reflexes are depressed with propofol making the 
 tracheal intubation and insertion of LARYNGEAL MASK AIRWAY 
easier than with thiopentone. 
Cardiovascular system : 
 The prominent effect of propofol is a decrease in arterial blood 
pressure during induction of anaesthesia.  The decrease in arterial blood 
pressure is associated with decrease in cardiac output and stroke volume 
and systemic vascular resistance.  The decrease in systemic pressure 
following induction is due to both vasodilation and myocardial 
depression.  The heart rate does not change significantly after the 
induction dose of propofol.  It is suggested that propofol either resets or 
inhibits the baro receptor reflex.  Propofol should be cautiously 
administered to patients with limited cardiac reserve or hypovolemia in 
whom a fall in peripheral vascular resistance or cardiac output might be 
disadvantageous. 
Hepatic and Renal function : 
 Propofol does not adversely affect hepatic or renal function as 
reflected by measurement of liver transaminase enzymes or creatinine 
concentration.  Prolonged intravenous infusion of propofol may result in 
excretion of green urine reflecting the presence of phenols in urine. 
 
 Coagulation : 
 Propofol does not alter tests of cogulation or platelet function. 
Site of injection : 
 Pain on injection of propofol occurs in fewer than 10% of patients, 
when it given into a large arm vein than into a small dorsal vein. 
Other effects : 
 Propofol does not block the secretion of cortisol following single 
dose or as continuous infusion.  Excitatory responses such as 
hypertonous, tremor, hiccough or spontaneous movements may be seen.  
Propofol does not trigger malignant hyperthermia.  Propofol reduces IOP 
markedly more than thiopentone on induction.  The vehicle for propofol 
does not contain antibacterial preservative, hence strict asepsis to be 
maintained when handling the drug. 
Dosage and Administration : 
1.  Induction of General Anaesthesia  
 1.0 – 2.5 mg / kg reduced in patients over 55 years of age. 
2.  Maintenance of General anaesthesia 80-150 microgram / kg / min IV 
combined with N2O or an opiate and reduced in the patients over 50. 
3.   Sedation 10-50 microgram / kg / min iv 
 
 Indications : 
1. Induction and maintenance of general anaesthesia 
2. For sedation during surgery 
3. For outpatient anaesthesia 
4. For sedation in ICU 
5. To treat nausea in post operative period or following 
chemotherapy 
6. To relieve cholestatic pruritus as well as pruritus induced by 
spinal opiates. 
 
 
 
 
 
 
 
 
 
 
 
 MIDAZOLAM  
 Midazolam is an imidazobenzodiazepine derivative, synthesized by 
Fryer and Walser in 1976. 
Chemical Properties : 
 Midazolam has a fused imidazole ring that is different from classic 
benzodiazepines.  The imidazole ring accounts for the basicity, stability 
in an aqueous solution and rapid metabolism. The pK of midazolam is 
6.15 which permits the preparation of salts that are water soluble.  The 
parentral solution of midzolam used clinically is buffered to an acidic pH 
of 3.5.  This is important because midazolam is characterized by a pH 
dependent ring opening phenomena in which the ring remains open at 
values of < 4, thus maintaining water solubility of the drug.  The ring 
closes at pH values of > 4 as when the drug is exposed to physiologic pH, 
thus converting midazolam to  highly lipid soluble drug. 
Mechanism of action : 
 Midazolam appear to produce all their pharmacological effects by 
facilitating the action of gamma aminobutyric acid (GABA)  the principal 
inhibitory neurotransmitter in central nervous system. It binds with 
GABAA receptor and enhances the opening of chloride gating channels 
resulting in increased chloride conductance, producing hyperpolarization 
 of the post synaptic cell membrane and rendering post synaptic neurons 
more resistant to excitation.  This resistance to excitation is presumed to 
be the mechanism by which midazolam produce anxiolysis, sedation, 
anticonvulsant, and skeletal muscle relaxant effects. 
Pharmacokinetics : 
 Midazolam is highly protein bound about 95%.  The drug follows 
the usual distribution pattern to vessel rich tissues and later to the poorly 
perfused fat.  Elimination is then dependent on hepatic biotransformation, 
which converts it into 4-hydroxymidazolam, a metabolite almost devoid 
of pharmacological activity. The initial redistribution is shorter and 
elimination phase (t ½ β = 2.3 hrs) is also rapid, contributing to more 
rapid recovery. 
Effects on organ systems : 
Central nervous system : 
 Midazolam produces decrease in cerebral metabolic oxygen 
requirements and cerebral blood flow.  Midazolam has anxiolytic, 
hypnotic and anterograde amnestic effects.  Midazolam is a potent 
anticonvulsant, effective in treatment of status epilepticus.  This effect is 
mediated through glycine receptors in the spinal cord.  It also possesses 
antinociceptive effect, when given intrathecally or epidural injection. 
 Cardiovascular system : 
 Midazolam produces decrease in systemic blood pressure and 
increase in heart rate.  Cardiac output is not altered by midazolam, 
suggesting that blood pressure changes are due to decrease in systemic 
vascular resistance. 
Respiratory system : 
 Midazolam produces dose-dependent decrease in ventilation.  
Patients with chronic obstructive pulmonary disease experience greater 
midazolam induced depression of ventilation. 
Clinical Uses : 
1. In preoperative medication 
2. For intravenous sedation 
3. Induction and maintenance of anaesthesia 
4. It is a potent anticonvulsant for the treatment of grandmal 
seizures. 
Dose : 
 Premedication  : 0.5 mg / kg oral, 0.05-0.1mg/kg IM 
 Induction   : 0.05 – 0.15 mg / kg IV 
 Maintenance  : 0.05 mg / kg IV 
 Sedation   : 0.5 – 1 mg IV 
 FENTANYL  
 
 Fentanyl is a phenylpiperdine derivative synthetic opioid agonist 
that is structurally related to pethidine.  As an analgesic, fentanyl is 75 to 
125 times more potent than morphine. 
 
Mechanism of action : 
 Fentanyl acts as an agonist at stereospecific opioid receptors at 
presynaptic and post synaptic sites in the central nervous system and 
outside the CNS in peripheral tissues.  The principal effect of opioid 
receptor activation is a decrease in neurotransmission.  This decrease in 
neuro transmission occurs largely by presynaptic inhibition of 
neurotransmitter (Acetylcholine, dopamine norepinephrine, substance  P) 
release. 
 Opioid receptors are classified as mu, delta, and kappa receptors.  
These receptors belong to a super family of G (Guanine) protein-coupled 
receptors. 
 
 
 
 Effects of opioid receptors : 
Mu1 Mu2 Kappa Delta 
Analgesia 
(supraspinal, spinal) 
 
Euphoria, miosis 
 
Bradycardia, 
hypothermia 
 
Urinary retention 
low abuse potential 
 
Decreased GI 
mobility, nausea 
vomiting 
Analgesia 
(Spinal) 
 
Depression 
of ventilation 
 
Physical 
dependence 
 
Constipation 
Spinal 
Analgesia 
 
Dysphoria 
sedation 
 
Miosis 
Supraspinal and 
spinal analgesia 
 
Physical 
dependence 
 
Urinary 
retention 
 
Pharmacokinetics : 
 Fentanyl has greater potency and rapid onset of action which 
reflects the greater lipid solubility compared with that of morphine.  The 
lungs exert a significant first-pass effect and transiently take up 
approximately 75 percent of an injected dose of fentanyl. Approximately 
80% of fentanyl is bound to plasma proteins and significant amounts 
 (40%) are taken up by red blood cells because the pKa of Fentanyl is high 
(8.4) at physiologic pH, it exists mostly in the ionized form. 
 Fentanyl is primarily metabolized in liver by N-dealkylation and 
hydroxylation.  Fentanyl has a high hepatic clearance and a high hepatic 
extraction ratio.  Norfentanyl, the primary metabolite is detectable in the 
urine for up to 48 hrs after IV fentanyl. 
 Fentanyl has a longer elimination half time 3.1 to 6.6 hours.  This 
longer elimination half time reflects a larger volume of distribution 335 
liters.  The context sensitive half time is 260 minutes for 4 hour infusion. 
Effects on organ system : 
Cardiovascular system : 
 Fentanyl slows atrioventricular node conduction and prolong AV 
node refractory period.  Fentanyl also has depressant effect on 
baroreceptor  reflex control of heart rate.  These effects will lead on to 
bradycardia.  In comparison with morphine, fentanyl even in large doses 
does not evoke the release of histamine.  As a result, dilatation of venous 
capacitance vessels leading to hypotension is unlikely. 
Central nervous system : 
 Fentanyl produce modest decreases in cerebral metabolic rate, 
cerebral blood flow and intra cranial pressure.  Fentanyl can produce 
 neuro excitation or arousal.  Seizure activity has been described to follow 
rapid IV administration of fentanyl. 
 Fentanyl can increase muscle tone and may cause muscle rigidity.  
This side effect is probably related to a catatonic state which can be 
induced by opioids. 
Respiratory System : 
 Fentanyl has dose-dependent depression of respiration, primarily 
through a direct action on brain stem respiratory centres. Fentanyl also 
decrease hypoxic ventilatory drive. 
 Fentanyl has therapeutic effects like antimuscarinic, 
antihistaminergic and antiserotoninergic actions and may be effective in 
patient with bronchial asthma.  Fentanyl has depressant effect on upper 
airway, tracheal and lower respiratory airway reflexes. 
Gastro intestinal tract  
 Like other opioids fentanyl produce nausea, vomiting, decrease GI 
motility and produces biliary spasm. 
Clinical uses and dose : 
1. Fentanyl as a loading dose 2-6 μg/kg along with sedative 
hypnotic can be used as an anaesthetic induction. 
 2. For maintenance of anaesthesia intermittent boluses of 25-50 μg 
every 15-30 mts or constant infusion of 0.5-5 μg/kg/hr. 
3. Can be used as high dose opioid anaesthesia in opioid induction. 
Dose varies between 20 and 50μg/kg 
4. Dose of 2-5 μg/kg can be used to attenuate hypertensive 
response before intubation. 
Preparations : 
 Fentanyl is available as 2 ml and 10ml ampoules, each ml provides 
fentanyl citrate equivalent to 50 μg of fentanyl. 
 Transdermal fentanyl patches are available in 25, 50, 75, 100 
μg/hour sizes that provide drug for 2-3 days. 
 Oral transmucosal fentanyl citrate (OTFC) is a solid dosage form of 
fentanyl that consists of fentanyl incorporated into a sweetened lozenge 
on a stick –lollipop.  OTFC  is available in 200, 300, 400 μg units, with 
doses range from 5-15μg/kg.  OTFC in useful as premedication in 
children before surgery and painful procedures. 
 
 
 
 
 REVIEW OF LITERATURE 
1.  RAVIKUMAR KOPPULA, ANITHA SHENOY, 2005 (J Anaesth 
Clinical Pharmacol), assessed the quality and ease of LMA insertion 
following induction of anaesthesia with either Propofol 2.5 mg/kg or 8% 
sevoflurane with fentanyl as co-induction agent in both groups.  They 
observed that the time to loss of verbal contact was faster with 
sevoflurane than with propofol and the clinical conditions for LMA 
insertion were equally good with both techniques of induction. 
2.  V. PRIYA, JV DIVATIA, D. DASGUPTA, 2002 (Indian J of 
Anaesth),  conducted  a randomized, double blinded trial to compare the 
conditions for LMA insertion after induction of anaesthesia with either 
8% sevoflurane in 50% N2O and O2 or intravenous propofol in ASA I or 
II female patients.  Loss of eyelash reflex was considered as the end point 
of induction.  They found that induction was more rapid with propofol 
than sevoflurane and excellent conditions for LMA insertion were 
obtained in a significantly greater number of patients in propofol group 
than in sevoflurane group.  They concluded that propofol is better than 
sevoflurane for LMA insertion using the loss eyelash reflex as the end 
point of induction while sevoflurane may provide an alternative to IV 
propofol for insertion of LMA. 
 3. KATI I et al, 2003 (The Tokohu Journal of experimental 
Medicine),  compared the haemodynamic changes, LMA insertion time 
and complications in patients anaesthetized with 6% sevoflurane in 50% 
N2O and O2 or propofol 2.5 mg/kg. LMA insertion time was found to be 
significantly longer in sevoflurane group than in propofol group and 
mean arterial blood pressure was significantly lower within each group. 
Apnea was significantly higher in propofol group than in sevoflurane 
group. They concluded that sevoflurane is an alternative to propofol for 
induction of anaesthesia and has a lower incidence of apnea. 
 
4.  ME MOLLOY et al, 1999 (Canadian J Anaesth), studied the 
conditions for LMA insertion obtained by propofol 2.5 mg /kg IV and 8% 
sevoflurane with 50% N2O and O2 by modified vital capacity breaths.  
The time for loss of consciousness was quicker in sevoflurane group than 
in propofol group but the time to successful insertion of LMA was longer 
than propofol group.  They observed that the duration of apnea was 
longer in propofol group compared to sevoflurane  group.  Their 
conclusion was, modified vital capacity breath inhalational induction 
with 8% sevoflurane in efficient for LMA insertion in most cases but 
requires more time than with propofol. 
 5)  LIAN KAH TI et al, 1999(Anaesthesia and analgesia), performed a 
prospective randomized controlled trial to compare the quality and ease 
of LMA insertion after a single vital capacity breath of 8% sevoflurane or 
IV propofol 3 mg/kg in unpremedicated patients.  Their result showed 
that, LMA was inserted more rapidly in propofol group of patients than 
sevoflurane group, greater incidence of initially impossible mouth 
opening in the sevoflurane group, the degree of attenuation of laryngeal 
reflexes was similar, apnea was more frequent in propofol group, both 
groups had stable haemodynamics profiles and good patient satisfaction.  
They concluded that sevoflurane vital capacity breath induction compares 
favourably with IV propofol induction for LMA insertion in adults.  
However, prolonged jaw tightness after the sevoflurane induction of 
anaesthesia may delay LMA insertion. 
 
6.  SMITH CE et al, 2000 (J Clinic Anaesth), compared LMA insertion 
condition in sevoflurane : N2O Vs Propofol in a prospective randomized 
study. The time to loss of consciousness was faster after propofol than 
sevoflurane : N2O. All patients in propofol group had apnea compared 
with 4 patients in sevoflurane group.  Heart rate was lower 5 and 10 min 
after LMA insertion in the sevoflurane group. They concluded as 
 sevoflurane - N2O and propofol provided comparable conditions for 
LMA insertion. 
 
7.  SAHAR M SIDDIK  et al, 2005 (Anaesthesia and Analgesia)  
investigated the incidence of LMA insertion at the first attempt and the 
incidence of side effects after LMA insertion using the combination of 
sevoflurane and propofol as compared with either sevoflurane or propofol 
alone for induction of anaesthesia in 83  unpremedicated patients of ASA 
physical status I & II.  Results showed that induction of anaesthesia using 
the combination of sevoflurane and propofol resulted in the most 
successful LMA insertion at first attempts and was associated with 
significant decrease in apnea as compared with propofol group. 
 
8. LOUIS PHILLIPPE FORTIER et al, 2006 (Canadian J Anaesth) 
assessed the conditions for LMA insertion in 8% sevoflurane induction 
using fentanyl 0.6mg / kg and midazolam 9μg/kg as intravenous 
premedication 5 minutes before induction. LMA insertion was successful 
in all patients with one or two attempts. Induction time and time to LMA 
insertion was more shorter in fentanyl - midazolam premedication group.  
Blood pressure and heart rate both are lower in premedication group. 
  
9. NAKAZAWA K et al, 1999 (European Journal of 
Anaesthesiology),used pretreatment with fentanyl and midazolam for 
LMA insertion using propofol in 60 patients.  They observed that blood 
pressure in fentanyl group was significantly lower than in midazolam 
group and pretreatment with midazolam 0.05 mg/kg with propofol 2.5mg 
/ kg provides safe and satisfactory conditions for LMA insertion. 
 
10.  THAWAITES  A et al, 1997 (British Journal of Anaesthesia), 
conducted a randomized, double blind comparison of 8% sevoflurane and 
propofol as induction agents for day-case cystoscopy in 102 patients.  
Anaesthesia was induced with propofol IV or inhalation of 8% 
sevoflurane.  They observed that induction time was slower with 
sevoflurane than propofol and was associated with less hypotension in 
sevoflurane group than with propofol group. 
 
 
 
 
 
 MATERIALS AND METHODS 
This is a prospective randomized study conducted at Government 
Rajaji Hospital, attached to Madurai Medical College, Madurai. 
After obtaining approval by the ethics committee and informed 
consent, a total of 60 patients belonging to ASA physical status 1 and 2 
of either gender and aged between 15-65 yrs, scheduled for elective 
general and urological procedures were enrolled for this study.  Patients 
requiring endotracheal intubation, morbidly obese, anticipated difficult 
airway with Mallampatti class 3 & 4, pregnant patients and those with 
history of  gastro esophageal reflex were excluded from this study. 
All patients were kept on overnight starvation.  They were 
premedicated with inj. glycopyrrolate 0.2 mg IM 30 minutes   prior to 
induction of anaesthesia.  The patients were randomly allocated to one of 
the two groups. 
Group S :  Inhalation induction using 8 % sevoflurane  
Group P :  Intravenous induction with propofol 2 mg / kg 
Monitoring consisted of pulse rate, oxygen saturation (SPO2) and 
non invasive blood pressure at one minute intervals up to 5 minutes of 
induction. 
After recording the base line values, all patients received 
midazolam 0.05 mg/kg and fentanyl 2 μg/kg.  They were then 
preoxygenated with 100% O2 for 3 minutes. 
 Group P : 
 Patients received propofol 2mg / kg  body weight with 100% O2 
via face mask through Magill’s circuit. 
Group S : 
 Patients received 8% sevoflurane( concentration calibrated Drager-
vapor 19.n vaporizer) with 50 % N2O and O2 each at fresh gas flow rate 
of 6 lit/ min.  through Magill’s circuit.  The patients were instructed to 
take breaths as deep as possible. (modified vital capacity breath ) 
 The loss of verbal contact was considered as the desired end-point 
for induction in both the techniques, which was assessed by the response 
to calling out the patient’s name. After loss of response to verbal contact, 
appropriate size LMA was inserted by the same person having 4years of 
experience in anaesthesiology and 2 years of experience in LMA 
insertion. The LMA was inserted by the standard technique as described 
by Dr. Brain.  During LMA insertion, the person who inserts the LMA 
will assess the ease of LMA insertion. 
 The following observation are made 
1. The time for induction ie. The time (in secs) taken from 
induction of anaesthesia to loss of verbal contact. 
2. Conditions for LMA insertion and patients response. 
 
 
  
They were graded on a three point scale using the following 
variables. 
Sl.No. Clinical Finding Grade Description 
1. Jaw muscle relaxation 3 
2 
1 
Full 
Partial 
Difficult 
2. Ease of LMA insertion 3 
2 
1 
Easy 
Difficult 
Impossible 
3. Coughing 3 
2 
1 
Nil 
Transient 
Persistent 
4. Gagging 3 
2 
1 
Nil 
Transient 
Persistent 
5. Laryngospasm / Airway 
obstruction 
3 
2 
1 
Nil 
Partial 
Total 
6. Patient movements 3 
2 
1 
Nil 
Moderate 
Vigorous 
 
 
 
 The overall conditions for LMA insertion were assessed as 
excellent, satisfactory or poor on the basis of the total score obtained by 
summing up the individual scores of each components.  Maximum total 
score 18. Excellent if 18,  satisfactory if 16&17, and poor if <16. 
3. Haemodynamic parameters, (blood pressure and pulse rate) were 
recorded at baseline, and every minute for five minutes after 
induction. 
After insertion of LMA, the cuff has inflated with the prescribed 
volume of air. Size 3 or 4 LMA was used in this study.  After securing 
the LMA,   anaesthesia was maintained with 66% N2O in Oxygen, 
halothane and non depolarizing muscle relaxants. 
 
Statistical Tools  
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002) 
developed by Centers for Disease Control and Prevention (CDC), Atlanta 
for W.H.O. 
 Using this software, frequencies, percentage, range, mean, standard 
deviation, x2 and 'p' values were calculated. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
 
 OBSERVATION AND RESULTS 
Table 1 : Age 
Propofol Group Sevoflurane Group Age Group 
 No % No % 
< 20 9 30 7 23.3 
20 – 29 9 30 12 40 
30 – 39 4 13.3 5 16.7 
40 – 49 5 16.7 4 13.3 
50 & Above  3 10 2 6.7 
Mean 29.43 years 28.67 years 
S.D 12.06 years 10.14 years 
'p' 0.9469 (Not significant) 
 
Table 2 : Sex 
Propofol Group Sevoflurane 
Group 
Sex 
 
No % No % 
Male 9 30 11 36.7 
Female 21 70 19 63.3 
'p' 0.7842 (Not significant) 
 
 Table 3 : Weight 
 
Weight in 
Kgs 
 
Propofol 
Group 
Sevoflurane 
Group 
Mean 50.57 49.6 
S.D 6.79 7.72 
'p' 0.6668 (Not Significant) 
 
 The demographic data of the patients included in this study showed 
no significant difference between both groups in terms of age, sex and 
weight.  
Table 4 :  Induction Time 
 
 
Induction time in 
minutes 
 
Propofol 
Group 
Sevoflurane 
Group 
Mean 44.17 50.07 
S.D 2.95 3.6 
'p' 0.0001  (Significant) 
 
 Induction time ie. Time to loss of verbal contact is rapid with 
propofol group compared with sevoflurane group. 
  
 
Table 5 : Jaw muscle relaxation 
 
Propofol  
Group 
Sevoflurane 
Group 
Jaw muscle 
relaxation 
 
No % No % 
Full (3) 27 90 18 60 
Partial (2) 3 10 12 40 
Difficult (1) - - - - 
Mean 2.83 2.6 
S.D 0.38 0.5 
P value  0.0467 (Significant) 
 
Jaw relaxation during LMA insertion was full and adequate in 90% 
in Group P compared with 60% in Group S.
  
 
 
Table 6 : Ease of LMA insertion 
 
Propofol  
Group 
Sevoflurane 
Group 
Ease of LMA 
insertion 
 
No % No % 
Easy (3) 27 90 25 83.3 
Difficult (2) 3 10 5 16.7 
Impossible (1) - - - - 
Mean score 2.9 2.8 
SD 0.31 0.38 
P 0.4513 (not significant) 
 
LMA insertion was easy in 90% of patients in group P as that of 
83% in  group S. No cases were impossible to insert LMA in both the 
groups. 
  
 
 
Table 7 : Coughing  
 
Propofol  
Group 
Sevoflurane 
Group 
Coughing  
 
No % No % 
Nil (3) 28 93.3 26 86.7 
Transient (2) 2 6.7 4 13.3 
Persistent (1) - - - - 
Mean score 2.93 2.87 
SD 0.25 0.35 
P 0.3934 (Not significant) 
 
Coughing was found to be present in 2 cases (6.7%) in Group 
P and 4 cases (13.3%) in Group S.
  
Table 8 : Gagging 
Propofol  
Group 
Sevoflurane 
Group 
Gagging 
 
No % No % 
Nil (3) 30 100 30 100 
Transient (2) - - - - 
Persistent (1) - - - - 
Mean score 3 3 
 
 
Table 9 : Laryngospasm / Airway obstruction 
 
Propofol  
Group 
Sevoflurane 
Group 
Laryngospasm / 
Airway 
obstruction 
 
No % No % 
Nil (3) 30 100 30 100 
Partial (2) - - - - 
Total (1) - - - - 
Mean score 3 3 
 
There was no gagging or laryngospasm like adverse effects in both 
the groups of patients.
  
 
 
Table 10 : Patient movements 
 
Propofol  
Group 
Sevoflurane 
Group 
Patient 
movements 
 No % No % 
Nil (3) 28 93.3 19 63.3 
Moderate (2) 2 6.7 11 36.7 
Vigorous (1) - - - - 
Mean score 2.93 2.63 
SD 0.22 0.26 
P 0.0122 (Significant) 
 
Moderate movement of the patient, either limbs or head, 
during LMA insertion was present in 6.7% of patients in Group P 
but in Group S with higher incidence of 36.7% which is also 
statistically significant. (P=0.0122).
  
 
 
 
Table 11 : Number of attempts 
 
Propofol  
Group 
Sevoflurane 
Group 
No. of attempts 
 
No % No % 
1 28 93.3 26 86.7 
2 2 6.7 4 13.3 
Mean 
S.D 
1.07 
0.25 
1.13 
0.35 
‘p’ 0.3934 (Not Significant) 
 
 LMA was successfully inserted in the first attempt in 93.3% of 
patients in Group P compared to 86.7% of patients in Group S which 
showed no significant difference statistically. 
 
 
 
  
 
Table 12 : Overall assessment 
 
Propofol  
Group 
Sevoflurane 
Group 
Overall 
assessment 
 No % No % 
Poor 1 3.3 5 16.7 
Satisfactory 5 16.6 10 33.3 
Excellent 24 80 15 50 
MEAN SCORE 17.67  16.87  
SD 0.8  1.48  
'p' 0.0099 ( Significant) 
 
 Excellent LMA inserting conditions were present in 80% of 
patients in Group P compared to that of 50% in Group S, satisfactory 
conditions in 16.6% of patients in Group P but 33.3% of patients in 
Group S and poor conditions were in 3.3% of patients in Group P and 
16.7% of patients in Group S.  This showed statistically significant 
excellent conditions for LMA insertion in Group P than in Group S. 
 
 
 
 
  
 
Table 13 : Pulse Rate 
 
Pulse Rate 
Propofol  
Group 
Sevoflurane  
Group 
Time in 
minutes 
Mean SD Mean SD 
‘p’ Significant 
0 99.43 11.61 97.63 12.79 0.8701 Not 
Significant 
1 73.37 10.91 84.83 12.3 0.0006 Significant 
2 74.87 11.63 83.4 13.67 0.0092 Significant 
3 77.1 10.76 85.4 14.54 0.0161 Significant 
4 80.23 10.46 88.7 14.75 0.0105 Significant 
5 83.0 10.3 90.83 14.77 0.0110 Significant 
 
 
 There was no significant difference between Group P and Group S 
in the baseline pulse rate, But group P patients showed a marked decrease 
in pulse rate, after induction upto 5 minutes, which is statistically 
significant than in Group S. 
 
 
 
 
  
 
Table 14 : Mean Arterial Pressure 
 
                     Mean Arterial Pressure 
Propofol  
Group 
Sevoflurane 
Group 
Time in 
minutes 
Mean SD Mean SD 
‘p’ Significant 
0 95.7 6.97 94.63 8.92 0.5338 Not Significant
1 73.83 5.02 83.97 7.91 0.0001 Significant 
2 74.63 5.01 83.47 8.05 0.0001 Significant 
3 76.43 4.49 83.17 8.57 0.0018 Significant 
4 78.87 4.48 88.7 9.35 0.0001 Significant 
5 82 4.93 90.97 8.87 0.0001 Significant 
 
Baseline mean arterial pressure in both groups showed no 
significant difference. But there is a significant decrease in mean arterial 
pressure in Group P upto 5 minutes after induction than in Group S.
       DISCUSSION 
 
 The common method of anaesthetic induction for laryngeal mask 
airway insertion is the use of intravenous propofol which has the 
advantage of rapid onset, short duration of action and depression of 
airway reflexes.  However  adverse  effects have been associated with 
propofol including hypotension, greater respiratory depression (apnea) 
and pain on injection. Recently sevoflurane has been widely used as an  
agent for inhalational induction.  It is suitable for quick inhalational 
induction in high concentrations because of its low blood gas solubility 
and minimal respiratory irritant effect.  
 The vital capacity induction technique with sevoflurane was used 
to make the technique similar to that of intravenous bolus injection of 
propofol.  But the modified vital capacity breath induction with 
sevoflurane is convenient. We used Magill’s system for both 
preoxygenation and induction with 8% sevoflurane in Group S and 
propofol 2mg/kg in Group P. Fentanyl was used as a coinduction agent 
because of known synergistic effect of opioids with both sevoflurane and 
propofol. 
 
 Induction Time : 
 The time to loss of verbal contact, indicating the end point of 
induction was 44.17+2.95 sec in group P compared to 50.07 + 3.6 sec in 
Group S.  This correlates well with the study PRIYA et al who showed 
that the induction time in group P was 41.7 + 10.1 sec and in Group S 
was 51.1+10.4 sec. Hence the induction was more rapid with IV propofol 
than with 8% sevoflurane. 
 KATI et al also found that induction was significantly longer in 
sevoflurane group as compared to propofol group. In a related study, 
MUZI et al also achieved insertion of LMA after sevoflurane induction 
in 1.7 minutes which was longer than with propofol group. 
 
Successful insertion at first attempt : 
 The successful insertion at first attempt was more in group P 
(93.3%) than group S (86.7%) which was statistically insignificant 
(p=0.3934).  This is also comparable to study by RAVIKUMAR 
KOPPULA et al who had successful insertion at first attempt in 95% in 
both groups and PRIYA et al had 84% in both groups. 
 
 
 Patient’s response to LMA insertion : 
 A full jaw muscle relaxation was achieved in 90% of patients in 
Group P and 60% of patients in Group S.  This is similar to study by 
PRIYA et al who had adequate jaw opening in 82% in Group P and 54% 
in Group S.  This is due to the well known effect on jaw muscles by 
propofol whereas inhalational anaesthetics may cause an increased 
muscle tone and spasticity.  Therefore, for a similar end point of 
induction ie. loss of verbal contact, there may be greater jaw muscle 
relaxation with propofol. 
 Moderate movements, either head or limbs, are present only in 
6.7% of patients in Group P compared to 36.7% in Group S which is 
statistically significant.  This is similar to the study by MARY E 
MOLLOY et al who had head or limb movements in 34% of patients in 
Group S and 9.3% in Group P. 
 The other adverse responses like coughing, gagging and 
laryngoscopasm were did not reach statistical significance in this study 
which is similar to MARY & MOLLOY et al study who showed that 
the modified vital capacity inhalational technique with sevoflurane is 
associated with less airway complications and also provides good 
conditions for LMA insertion, especially when used with 50% N2O in 
 O2.  IAN SMITH  et al also revealed that inhalational induction with 
sevoflurane was not associated with clinical signs of respiratory irritation, 
coughing, laryngospasm or excessive oral secretions.  KOPPULA et al 
also showed coughing in only one patient and no incidence of gagging 
and laryngospasm which also correlates with this study. 
Overall conditions for LMA insertion : 
 Excellent inserting conditions with minimal adverse reactions were 
seen in more number of patients in Group P.  In group P excellent 
conditions were seen in 84% of the patients whereas in Group S in 50% 
of patients. Analysis of the total scores for conditions for LMA insertion 
was done. The mean score in Group P was 17.67 + 0.8 and in Group S 
was 16.87 + 1.48 with ‘p’ value of 0.0099 which is statistically 
significant.  This is similar to the study by PRIYA et al for whom the 
mean score was 17.5 + 0.77 in Group P and 16+1.15 in Group S 
(p=0.012).  Hence LMA insertion was superior with propofol than with 
sevoflurane. 
Haemodynamic Parameters : 
 In Group P, the decrease in pulse rate and mean arterial pressure 
after induction upto 5 minutes was statistically significant when 
compared to Group S in this study.  This results were similar and 
 comparable with the study done by THWAITES A et al who showed 
induction of anaesthesia with propofol was associated with a decrease of 
approximately 20 mm of Hg in MAP occurred within 2 minutes and 
persisted for atleast 10 minutes in contrast to the decrease in MAP with 
sevoflurane was only 10 mm of Hg and MAP had returned to the baseline 
values within 5-7 minutes. 
 This results also correlates well with study of PRIYA et al who 
showed statistically significant difference in MAP in the propofol group. 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY  
 
 The aim of this study is to compare the induction time, overall ease 
of LMA insertion and haemodynamic changes in sevoflurane and 
propofol group.  Sixty adults of ASA I & II physical status patients 
undergoing elective surgery requiring LMA insertion were randomly 
allocated to induction with either 8% sevoflurane or propofol 2 mg / kg 
after receiving fentanyl 2 μ / kg and midzolam 0.05 mg/kg IV irrespective 
of the groups.  The time for induction ie. loss of verbal contact was noted 
in both groups.  Then immediately LMA was inserted during which ease 
of LMA insertion, jaw relaxation and other adverse responses were also 
noted.  Pulse rate and mean arterial pressure were measured before 
induction of anaesthesia and upto 5 minutes after induction. 
 Of the two groups compared in this study, the induction time in 
propofol group was rapid (44.17+2.95sec) and also inserted in first 
attempt in 93.3% of patients.  It also offered excellent conditions in 80% 
and satisfactory conditions in 16.6% of patients for LMA insertion with 
minimal adverse response. But the decrease in mean arterial pressure and 
pulse rate was statistically significant compared with baseline, but was 
not regarded as clinically significant. 
  In sevoflurane group, the induction time was little prolonged (50.07 
+ 3.6sec) comparing with propofol and successful insertion at first 
attempts was 86.7% which is comparable to the propofol group.  The 
overall conditions for LMA insertion was excellent in 50% and 
satisfactory in 33.33% of patients with adverse responses like moderate 
movements of the patients.  The decrease in pulse rate and mean arterial 
pressure was not statistically significant when compared to propofol 
group. 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
CONCLUSION 
 
To conclude,  propofol induction is better for insertion of  LMA in 
terms of shorter induction period i.e. time to loss of verbal contact and  
excellent conditions provided for LMA insertion with minimal adverse 
responses like movement of the patients and coughing.  8% sevoflurane 
inhalational induction has longer induction period when compared with 
propofol and provides satisfactory conditions for LMA insertion with 
moderate adverse responses.  But the haemodynamic variability ie., 
decrease in pulse rate and fall in blood pressure were significant with 
propofol induction than in 8% sevoflurane.  Hence, the modified vital 
capacity breath induction with 8% sevoflurane may be an alternative to 
IV propofol induction where the haemodynamic alterations are to be 
avoided for insertion of LMA in adult patients. 
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 PROFORMA 
COMPARISON OF SEVOFLURANE VERSUS PROPOFOL FOR 
LMA INSERTION IN ADULTS 
 
Patient Name:      Age  :  Sex : 
Address   :      IP No.:  Wt  : 
 
Diagnosis   : 
Surgery : 
ASA Risk : 
Air way : 
Preoperative Clinical features : 
 
Premedication  : 
Induction Agent : 
Adjuvants  : 
Observation : 
 I . Time taken from start of induction to loss of verbal contact 
 II. Overall conditions for LMA insertion 
 
 Sl.No. Clinical Finding Grade Description 
1. Jaw muscle relaxation 3 
2 
1 
Full 
Partial 
Difficult 
2. Ease of LMA insertion 3 
2 
1 
Easy 
Difficult 
Impossible 
3. Coughing 3 
2 
1 
Nil 
Transient 
Persistent 
4. Gagging 3 
2 
1 
Nil 
Transient 
Persistent 
5. Laryngospasm / Airway 
obstruction 
3 
2 
1 
Nil 
Partial 
Total 
6. Patient movements 3 
2 
1 
Nil 
Moderate 
Vigorous 
III – Analysis of haemodynamic changes : 
Time after start of anaesthetic induction (minutes)  
0 1 2 3 4 5 
BP       
PR       
SPO2       
 
  
 
 
  
FENTANYL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
MIDAZOLAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
PROPOFOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SEVOFLURANE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
LMA - CLASSIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          STANDARD TECHNIQUE OF LMA INSERTION 
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years kgs sec.  /min mmHg  /min mmHg  /min mmHg  /min mmHg  /min mmHg  /min mmHg
1 Indrani 2741 33 F 45 55 full easy n n n M 1 satisfactory 92 104 81 91 84 93 86 91 89 98 89 99
2 Amutha 3944 27 F 48 50 full easy n n n n 1 excellent 104 82 90 78 88 77 90 75 98 80 98 82
3 Ponraj 4778 16 M 43 56 partial easy t n n M 1 poor 92 87 78 80 68 76 76 76 80 82 80 83
4 Lakshmanan 4681 52 M 51 54 full easy n n n n 1 excellent 96 90 78 83 59 81 64 81 68 85 74 86
5 Sakunthala 3476 25 F 42 52 full easy n n n n 1 excellent 92 101 79 87 80 86 80 88 82 91 85 95
6 Rajalaksmi 6164 32 F 67 50 full easy n n n n 1 excellent 112 105 96 93 90 91 90 95 92 97 92 101
7 Ilayaraja 5493 16 M 40 50 partial easy n n n n 1 satisfactory 103 98 90 88 88 90 92 89 92 96 94 98
8 Rajendran 1090 22 M 60 48 full easy n n n n 1 excellent 79 87 74 75 72 74 69 73 78 75 80 82
9 Jeyakodi 5027 50 F 65 45 full easy n n n n 1 excellent 112 95 94 82 90 87 88 86 94 93 98 94
10 Rabiyath 6370 32 F 52 43 full easy n n n n 1 excellent 114 114 102 95 100 94 104 93 110 104 113 106
11 Valarmathy 3955 33 F 40 52 full easy n n n n 1 excellent 92 101 82 94 79 89 84 88 86 95 89 97
12 Gomathy 4158 35 F 45 50 full easy n n n n 1 excellent 82 83 68 70 62 70 64 71 64 73 66 77
13 Muthaiah 4807 28 M 52 56 partial easy n n n M 1 satisfactory 64 87 56 82 53 78 57 75 59 88 59 95
14 Joshi 4985 26 M 60 45 partial diff n n n n 1 satisfactory 111 103 99 93 100 94 108 96 116 98 118 97
15 Raja 501426 22 M 54 48 full easy n n n M 1 satisfactory 74 83 70 73 69 71 60 70 62 78 64 80
16 Angulakshmi 503086 25 F 34 58 partial diff t n n M 2 poor 86 83 80 74 72 70 70 67 75 71 78 75
17 Chinnaponnu 21456 45 F 52 52 partial easy n n n n 1 satisfactory 88 90 64 73 69 77 70 79 72 82 76 85
18 Lalinabanu 21464 23 F 45 50 full easy n n n n 1 excellent 96 89 82 79 81 79 86 76 88 82 91 85
19 Periyatchi 22466 17 F 50 46 partial diff t n n M 2 poor 88 101 70 97 71 91 70 91 78 97 80 97
20 Sangili 23903 40 M 60 52 full easy n n n n 1 excellent 102 108 90 97 92 94 94 91 94 101 96 102
21 Rathinam 25522 45 M 45 48 full easy n n n n 1 excellent 112 106 100 91 101 96 106 95 110 101 110 101
22 Jeyapriya 20404 20 F 42 44 full easy n n n n 1 excellent 98 97 86 89 88 89 94 87 96 99 98 101
23 Sujatha 22507 40 F 52 48 partial diff t n n M 2 poor 112 105 102 90 100 89 96 92 102 99 106 102
24 Muthuselvi 22136 27 F 55 50 partial diff t n n M 2 poor 112 87 106 76 100 77 106 81 106 81 108 83
25 Senthilselvi 24102 19 F 46 48 full easy n n n n 1 excellent 104 95 86 82 86 83 91 81 94 87 97 89
26 Lakshmi 15654 28 F 50 52 partial easy n n n M 1 satisfactory 106 92 92 81 96 83 96 83 98 85 98 89
27 Karthik 15064 26 M 50 52 full easy n n n n 1 excellent 98 87 80 82 82 77 84 76 86 81 86 83
28 Rathna 16863 19 F 40 50 full easy n n n M 1 satisfactory 90 83 81 75 84 73 87 71 88 78 90 77
29 Muthusamy 17532 18 M 53 48 partial easy n n n M 1 satisfactory 106 95 89 80 94 86 96 88 98 91 102 92
30 Geethaselvi 16818 19 F 50 50 partial easy n n n n 1 satisfactory 112 101 100 89 104 89 104 90 106 93 110 96
M - Moderate t  - Transient n -  Nil
